Commercializing Antimicrobial Products in the US Market
Commercializing antimicrobial products in the United States presents a complex intersection of scientific innovation, regulatory scrutiny, and market dynamics. Rising antimicrobial resistance has intensified the urgency for new treatments, yet developers must navigate challenging economic incentives and evolving regulatory frameworks before bringing products to market. Pharmaceutical companies, emerging biotech firms, and academic innovators are increasingly … Read more